BVTK yields 20000000.00% · JNJ yields 2.14%● Live data
📍 BVTK pulled ahead of the other in Year 1
Combined, BVTK + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BVTK + JNJ for your $10,000?
Bravatek Solutions, Inc. markets and distributes proprietary and allied security, defense, and information security software, hardware, and services in the United States and internationally. Its products include software, hardware, and services, as well as email security, user authentication, telecommunications, and cyber breach protection. These assist corporate entities, governments, and individuals in protecting their organizations and/or critical infrastructure against both physical and cyberattacks. The company's products include Ecrypt One, an email server with integrated security technology used to protect email and attachments in transit and at rest. It also offers telecommunication services, including cellular tower mapping and audits, ground audits, civil equipment installation, cellular site decommissioning, 3G/4G/5G installations, project/construction management, battery installation and maintenance, shelter and compound preventative maintenance, site cleanup, and other related services. The company has strategic alliances with Center for Threat Intelligence, LLC; OrangeHook, Inc.; KP Consulting; AG Capital Management, LLP; Optimized Fuel Technologies; MC Smart Controls; and RMA Armament, Inc. The company was formerly known as Ecrypt Technologies, Inc. and changed its name to Bravatek Solutions, Inc. in October 2015. Bravatek Solutions, Inc. was founded in 2007 and is based in Austin, Texas.
Full BVTK Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.